Drug intelligence / Profile preview

ORM-21444

Development stage: Unknown
Lead developer: Orion Pharma
Modality: Small Molecules
Administration: Oral

Overview

ORM-21444 is a selective androgen receptor modulator (SARM) developed by Orion Corporation. It is designed to exhibit tissue-selective activation of the androgen receptor, specifically targeting muscle and bone tissues to promote anabolic growth while minimizing undesirable androgenic effects on the prostate and other tissues. The compound is primarily being investigated for the treatment of sarcopenia and other muscle-wasting conditions. ORM-21444 has progressed into Phase 1 clinical development to evaluate its safety, tolerability, and pharmacokinetic profile in human subjects.

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on ORM-21444.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORM-21444.

Explore the full profile